医学
生殖器疣
入射(几何)
冷冻疗法
人口
儿科
妇科
外科
内科学
宫颈癌
环境卫生
光学
物理
癌症
作者
Réjean Thomas,Marc Steben,Zoë R. Greenwald,Melissa Stutz,Caroline Rodier,Fern DeAngelis,Emmanouil Rampakakis
出处
期刊:Sexually Transmitted Diseases
[Ovid Technologies (Wolters Kluwer)]
日期:2017-06-20
卷期号:44 (11): 700-706
被引量:16
标识
DOI:10.1097/olq.0000000000000666
摘要
Objectives The incidence of recurrent genital warts is not well characterized; this is especially true in a post-human papillomavirus (HPV) vaccination era. The objectives of this study were to assess the incidence of subsequent HPV-related external genital warts (EGW) episodes in high-risk male and female adults, as well as ascertain patient profile and disease characteristics, in a real-world Canadian sexual health clinical setting. Methods Retrospective chart review study conducted at Clinique médicale l’Actuel, a sexual health clinic in Montréal, Québec, Canada. Eligible patients were 18 to 45 years of age with a first diagnosis of EGW associated with a HPV infection between July 1, 2006, and June 30, 2012. Results A total of 400 first-episode EGW cases were identified. Up to 6 subsequent episodes were documented, with 194 (48.5%) patients reporting at least 1 subsequent EGW episode. Median time to first subsequent EGW episode was 3.97 years, and the incidence density rate for all subsequent episodes was 0.18/100 patient-years. Over 90% of patients reported clearance of the first subsequent episode, with median time to clearance of 0.30 years. Regardless of subsequent episode number, greater than 95% of patients received treatment, primarily cryotherapy, with high-risk sexual behavior reducing as number of episodes increased. Conclusions Overall, a high rate of subsequent EGW episodes was observed in this high-risk population, despite high treatment rates and improvement in high-risk sexual behavior. These data, assessed in a prevaccination Québec health care system, may be compared with future EGW rates to assess the impact of a governmentally-funded HPV vaccination program.
科研通智能强力驱动
Strongly Powered by AbleSci AI